Introduction
The 41 aa neuropeptide corticotropin-releasing factor (CRF) plays an important role in stress-induced drug-seeking behavior (Sarnyai et al., 2001 ). This depends primarily on CRF release in the ventral tegmental area (VTA), which receives CRF inputs from the paraventricular nucleus and the limbic forebrain (Rodaros et al., 2007) . Stress and addictive drugs sensitize VTA dopaminergic neurons to the effects of excitatory inputs by common synaptic modifications (Saal et al., 2003) , which can be reproduced by VTA application of CRF (Ungless et al., 2003) . In the VTA of cocaine-experienced but not naive animals, stressinduced CRF release increases extracellular levels of glutamate and dopamine (Wang et al., , 2007 . Of the two known CRF receptors (CRF 1 R and CRF 2 R), CRF 1 R is involved preferentially with stress-induced reinstatement of cocaine-seeking behavior and VTA dopamine release (Shaham et al., 1998; Lu et al., 2003; Lodge and Grace, 2005; Blacktop et al., 2011) .
The 33-and 28-aa-long neuropeptides orexin-A (hypocretin-A) and orexin-B (hypocretin-B) are expressed within cell bodies in the lateral hypothalamus and adjacent perifornical area (Sakurai et al., 1998; de Lecea et al., 1998) . These cells are the origin of an ascending arousal system that projects to the entire cortex, but apart from their well established role in arousal, orexins have a role in reward processes and substance-use disorders, which might depend on the dense orexinergic innervation of the dopaminergic cells of the VTA (Borgland et al., 2010; Mahler et al., 2014; Sakurai, 2014) . A dichotomy in orexin function appears to be related to the two identified orexin receptors, with reward and arousal being associated closely with activation of OX 1 R and OX 2 R, respectively (Borgland et al., 2010; Mahler et al., 2014) . The orexin-hypocretin system also drives cocaine reinstatement through activation of stress pathways, which includes the participation of CRF. Thus, central administration of orexin-A led to a dose-related reinstatement of cocaine seeking, which was prevented by a nonselective CRFR antagonist, and a selective OX 1 R antagonist blocked stress-induced reinstatement of previously extinguished cocaine-seeking behavior (Boutrel et al., 2005) .
The same as for CRF, VTA is a key brain area involved in the ability of the orexinergic system to promote cocaine seeking. Intra-VTA administration of orexin-A reinstated cocaine selfadministration, which was also associated with VTA glutamate and dopamine release . Intriguingly, although CRF and orexin-A are involved in stress-induced cocaine reinstatement by acting in the VTA, their mechanisms appeared independent . In the present study, we provide evidence for the existence of pharmacologically significant interactions between CRF and orexin-A that depend on CRF 1 R-OX 1 R oligomerization. CRF 1 R-OX 1 R heteromers are the conduits of a negative crosstalk between orexin-A and CRF observed in transfected cells and the VTA, in which they can significantly influence dendritic dopamine release. We also demonstrate that CRF 1 R-OX 1 R heteromers associate with 1 receptors ( 1 Rs) to form CRF 1 R-OX 1 R-1 R complexes and that cocaine binding to 1 R in the complex promotes a long-term disruption of the orexin-A-CRF negative crosstalk. Through this mechanism, cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A.
Materials and Methods

Ligands and HIV transactivator of transcription-linked peptides. (Ϫ)-
Cocaine HCl was purchased from Sigma and from the Spanish Agency of Medicine (number 2003C00220). 1 R ligands PD144418 (1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine oxalate) and PRE-084 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride, CRF, orexins, SB334867 (N-(2-Methyl-6-benzoxazolyl)-N-1,5-naphthyridin-4-yl urea), and NBI27914 [5-chloro-N-(cyclopropylmethyl)-2-methyl-Npropyl-NЈ-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride] were purchased from Tocris Bioscience. To allow intracellular delivery, a peptide or protein can be fused to the cell-penetrating HIV transactivator of transcription (TAT) peptide (YGRKKRRQRRR; Schwarze et al., 1999) . HIV TAT fused to a peptide with the amino acid sequence of a transmembrane domain (TM) of a GPCR can be inserted effectively into the plasma membrane as a result of both the penetration capacity of the TAT peptide and the hydrophobic property of the TM domain (He et al., 2011) . HIV TAT-fused peptides with the amino acid sequences of OX 1 R TM domains TM1, TM5, and TM7 were used (Genemad Synthesis) . To obtain the right orientation of the inserted peptide, HIV TAT peptide was fused to the C terminus of OX 1 R TM1, TM5, and TM7 peptides, with the following final amino acid sequences: WV-LIAAYVAVFLIALVGNTLVYGRKKRRQRRR, SCFFFVTYLAPL-GLMGMAYFQIFYGRKKRRQRRR, and YACFTFSHWLVYAN-SAANPIIYNFYGRKKRRQRRR, respectively.
Expression vectors, fusion proteins, and CRF 1 R mutants. Sequences encoding amino acid residues 1-155 and 156-238 of yellow fluorescent protein (YFP) Venus protein were subcloned in pcDNA3.1 vector to obtain YFP Venus hemitruncated proteins. Human cDNAs for OX 1 R, CRF 1 R, ghrelin 1a receptors [growth hormone secretagogue 1a receptor (GHS 1a R)], or 1 R, cloned into pcDNA3.1, were amplified without their stop codons using sense and antisense primers harboring the following: EcoRI and KpnI sites to clone CRF 1 R, OX 1 R, or GHS 1a R in pcDNA3.1RLuc vector (pRLuc-N1; PerkinElmer Life and Analytical Sciences) or pEYFP-N1 vector (enhanced yellow variant of GFP; Clontech), HindIII and BamHI sites to clone 1 R in pEYFP-N1 vector, or EcoRI and BamHI sites to clone CRF 1 Rs and OX 1 Rs in a Cherry containing vector (pcDNA3.1Cherry). Amplified fragments were subcloned to be in-frame with restriction sites of pRLuc-N1, pEYFP-N1, or pcDNA3.1Cherry vectors to provide plasmids that express proteins fused to Renilla Luciferase (RLuc), YFP, or Cherry on the C-terminal end (OX 1 R-RLuc, CRF 1 RRLuc, OX 1 R-YFP, CRF 1 R-YFP, GHS 1a R-YFP, 1 R-YFP, or CRF 1 RCherry). Dr. Marian Castro (University of Santiago de Compostela, Santiago de Compostela, Spain) generously provided human ␤-arrestin 2-RLuc6 cDNA, cloned in pcDNA3.1 RLuc6 vector (pRLuc-N1; PerkinElmer Life and Analytical Sciences). For bimolecular fluorescence complementation (BiFC) experiments, human cDNA for CRF 1 R was also subcloned into pcDNA3.1-nVenus to provide a plasmid that expresses the receptor fused to the hemitruncated nYFP Venus on the C-terminal end of the receptor (CRF1R-nVenus), and human cDNA for OX 1 R was also subcloned into pcDNA3.1-cVenus to provide a plasmid that expresses the receptor fused to the hemitruncated cYFP Venus on the C-terminal end of the receptor (OX 1 R-cVenus). Two CRF 1 R mutants were used: (1) CRF 1 R433, which lacks a large portion of the extracellular domain of the N terminus (amino acids 1-111) and is not able to bind ligands (Devigny et al., 2011) ; and (2) CRF 1 R432, with H405P and A119L mutations in the 3 IL that confer enhanced constitutive activity.
Cell clones, cell culture, and transient transfection. HEK-293T cells were grown in DMEM (Gibco) supplemented with 2 mM L-glutamine, 100 g/ml sodium pyruvate, 100 U/ml penicillin/streptomycin, minimal essential medium non-essential amino acids solution (1:100), and 5% (v/v) heat-inactivated fetal bovine serum (Invitrogen) and were maintained at 37°C in an atmosphere with 5% CO 2 . Cells were transiently transfected with the corresponding fusion protein cDNA by the polyethylenimine (Sigma) method. For receptor-heteromer signaling, 0.4 g of OX 1 RRLuc cDNA and 0.3 g of CRF 1 R-YFP cDNA were transfected, which provides 80 -90% of maximum bioluminescence resonance energy transfer (BRET), as deduced from the BRET saturation curves (Fig. 1) , indicating a high degree of receptor heteromerization. For the expression of GHS 1a R-YFP, equal amounts of GHS 1a R-YFP and GHS 1b R cDNA were transfected to ensure GHS 1a R expression at the cell membrane. HEK-293T stable cell lines expressing CRF 1 R-YFP or OX 1 R-YFP fusion proteins were created by transfection of the corresponding cDNA in a pcDNA3.1 plasmid. Antibiotic-resistant clones were isolated with 1000 g/ml geneticin (Invitrogen), and, after an appropriate number of passages, stable cell lines were selected and grown as above indicated in the presence of 500 g/ml geneticin. Sample protein concentration was determined as a control of cell number using a Bradford assay kit (Bio-Rad) with bovine serum albumin (BSA) dilutions as standards.
Fluorescence complementation assays. HEK-293T cells were cotransfected with 0.6 M CRF 1 R-nVenus cDNA and 0.6 M OX 1 R-cVenus cDNA; 48 h after transfection, cells were treated or not with the indicated HIV TAT-TM-fused peptides (4 M) for 60 min at 37°C. To quantify protein-reconstituted YFP Venus expression, cells (20 g of protein) were distributed in 96-well microplates (black plates with a transparent bottom; Porvair), and fluorescence was read in a Fluo Star Optima Fluorimeter (BMG Labtech) equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth excitation filter at 400 nm reading. Protein fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells not expressing the fusion proteins.
Resonance energy transfer experiments. For BRET assays, HEK-293T cells were transiently cotransfected with a constant amount of cDNA encoding for proteins fused to RLuc and with increasing amounts of the cDNA corresponding to proteins fused to YFP. To quantify protein YFP expression, cells (20 g of protein) were distributed in 96-well microplates (black plates with a transparent bottom), and fluorescence was read in the Fluo Star Optima Fluorimeter using a 10 nm bandwidth excitation filter at 400 nm reading. Protein fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells expressing the BRET donor alone. For BRET measurements, the equivalent of 20 g of cell suspension were distributed in 96-well microplates (Corning 3600, white plates; Sigma), and coelenterazine H (5 M; Invitrogen) was added. After 1 min, readings were obtained using a Mithras LB 940 (Berthold Technologies) that allows the integration of the signals detected in the short-wavelength filter at 485 nm and the longwavelength filter at 530 nm. To quantify protein RLuc expression luminescence, readings were also performed 10 min after addition of coelenterazine H (5 M). For sequential resonance energy transfer (SRET) assays, HEK-293T cells were transiently cotransfected with constant amounts of cDNAs encoding for both receptor fused to RLuc and YFP proteins and with increasingly amounts of cDNA corresponding to the receptor fused to Cherry protein. After 48 h of transfection, quantifications were performed in parallel in aliquots of transfected cells (20 g of protein): (1) quantification of receptor YFP or receptor RLuc expression was performed as indicated for BRET experiments; (2) for quanti-fication of receptor Cherry expression, cells were distributed in 96-well microplates (Corning black plates with a transparent bottom), and fluorescence was read in the Fluo Star Optima Fluorimeter using a 10 nm bandwidth excitation filter at 590-nm reading; and (3) for quantification of SRET, cells were distributed in 96-well microplates (black plates with a transparent bottom), and coelenterazine H (5 M) was added. After 1 min, the readings were collected using a using a Fluo Star Optima Fluorimeter that allows the integration of the signals detected in the shortwavelength filter at 530 nm and the long-wavelength filter at 590 nm. Net BRET and net SRET were defined as [(long-wavelength emission)/ (short-wavelength emission)] Ϫ Cf, where Cf corresponds to [(longwavelength emission)/(short-wavelength emission)] for the donor construct expressed alone in the same experiment. Both fluorescence and luminescence of each sample were measured before every experiment to confirm similar donor expressions (ϳ100,000 bioluminescence units) while monitoring the increase in acceptor expression (1000 -40,000 fluorescence units). BRET or SRET was expressed as milliBRET (mBU) or milliSRET (mSU) units (net BRET or SRET ϫ 1000). Data were fitted to a nonlinear regression equation, assuming a single-phase saturation curve with GraphPad Prism software (GraphPad Software). The relative amount of BRET or SRET is given as a function of 100 ϫ the ratio between the fluorescence of the acceptor (YFP or Cherry) and the Luciferase activity of the donor (RLuc).
Proximity ligation assay. For proximity ligation assays (PLAs), transfected cells were grown on glass coverslips and were fixed in 4% paraformaldehyde for 15 min, washed with PBS containing 20 mM glycine, permeabilized with the same buffer containing 0.05% Triton X-100, and washed successively with PBS. Heteromers were detected using the Duolink II in situ PLA detection Kit (OLink Bioscience) following the instructions of the supplier. To detect both OX 1 R-RLuc-CRF 1 R-YFP and OX 1 R-RLuc-GHS 1a R-YFP heteromers, a mixture of equal amounts of rabbit anti-RLuc antibody (EMD Millipore) and mouse anti-YFP antibody (Santa Cruz Biotechnology) was used and incubated with antirabbit plus and anti-mouse minus PLA probes. Cells were mounted using the mounting medium with DAPI. The samples were observed in a Leica SP2 confocal microscope equipped with an apochromatic 63ϫ oilimmersion objective (numerical aperture 1.4) and 405 and 561 nm laser lines. For each field of view, a stack of two channels (one per staining) and 9 -15 Z stacks with a step size of 1 m were acquired. Images were opened and processed with NIH Image J confocal.
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde for 15 min and washed with PBS containing 20 mM glycine (buffer A) to quench the aldehyde groups. After permeabilization with buffer A containing 0.2% Triton X-100 for 5 min, cells were treated with PBS containing 1% BSA. After 1 h at room temperature, cells were labeled with the primary mouse monoclonal anti-RLuc receptor antibody (1:200; Millipore) for 1 h to detect OX 1 R-RLuc, washed, and stained with the secondary Cy3 donkey anti-mouse antibody (1:200; Jackson ImmunoResearch). CRF 1 R fused to YFP protein were detected by their fluorescence properties. The samples were rinsed several times and mounted with a medium suitable for immunofluorescence (30% Mowiol; Calbiochem). Samples were observed in a Leica SP2 confocal microscope.
Rat VTA slices. Male Sprague Dawley rats (2 months old; animal facility of the Faculty of Biology, University of Barcelona) were used. The animals were housed two per cage and kept on a 12 h dark/light cycle with food and water available ad libitum, and experiments were performed during the light cycle. All procedures were approved by the Catalan Ethical Committee for Animal Use (CEAA/DMAH 4049 and 5664). Animals were killed by decapitation under 4% isoflurane anesthesia, and brains were rapidly removed, placed in ice-cold oxygenated (O 2 /CO 2 , 95%/5%) Krebs-HCO 3 Ϫ buffer (in mM: 124 NaCl, 4 KCl, 1.25 KH 2 PO 4 , 1.5 MgCl 2 , 1.5 CaCl 2 , 10 glucose, and 26 NaHCO 3 , pH 7.4), and sliced at 4°C using a brain matrix (Zivic Instruments). VTA slices (500 m thick) were kept at 4°C in Krebs-HCO 3 Ϫ buffer during the dissection; each slice was transferred into a 12-well plate with Corning Netwell inserts, containing 2 ml of ice-cold Krebs-HCO 3 Ϫ buffer. The temperature was raised to 23°C, and, after 30 min, the medium was replaced by 2 ml of fresh Krebs-HCO 3 Ϫ buffer (23°C). Slices were incubated under constant oxygenation (O 2 /CO 2 , 95%/5%) at 30°C for 4 h in an Eppendorf Thermomixer (5 Prime), and the medium was replaced by fresh Krebs-HCO 3 Ϫ buffer and incubated for 30 min before the addition of any agent. After incubation, the solution was discarded, and slices were frozen on dry ice and stored at Ϫ80°C until ERK1/2 phosphorylation was determined.
Akt and ERK1/2 phosphorylation. Cells or rat VTA slices were treated or not with the indicated ligands for the indicated time and were lysed by the addition of 300 l of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM ␤-glycerophosphate, 1% Triton X-100, 20 M phenyl-arsine oxide, 0.4 mM NaVO 4 , and protease inhibitor mixture). Cellular debris was removed by centrifugation at 13,000 ϫ g for 5 min at 4°C, and the protein was quantified by the bicinchoninic acid method using BSA dilutions as standard. Akt or ERK1/2 phosphorylation was then determined by Western blot as described previously , using a rabbit anti-phospho-Ser473 Akt antibody (1:2500; Signalway Antibody) for Akt phosphorylation or mouse anti-phospho-ERK1/2 antibody (1:2500; Sigma) and rabbit anti-ERK1/2 antibody that recognizes both phosphorylated and nonphosphorylated ERK1/2 (1: 40,000; Sigma).
␤-Arrestin 2 recruitment. Arrestin recruitment was determined as described previously . Briefly, BRET experiments were performed in HEK-293T cells 48 h after transfection with the cDNA corresponding to the indicated receptors fused or not to the YFP and ␤-arrestin 2-RLuc cDNA (0.5 g). Cells (20 g protein) were distributed in 96-well microplates (Corning 3600, white plates with white bottom; Sigma) and were incubated with the indicated antagonist for 10 min and stimulated with the agonist for 10 min before the addition of coelenterazine H (5 M; Invitrogen). After 1 min of adding coelenterazine H, BRET between ␤-arrestin 2-RLuc and receptor YFP was determined and quantified as described above.
cAMP production. Transfected HEK-293T cells were incubated in serumfree medium for 16 h before the experiment. Cells were preincubated for 15 min at 37°C with zardaverine (50 M; Tocris Bioscience) and treated for 15 min with the indicated concentration of agonists in the presence or absence of forskolin (0.5 M; Sigma). When indicated, receptor antagonists were preincubated 10 min before agonist addition. To stop the reaction, cells were placed on ice, washed with ice-cold PBS, and centrifuged at 2500 ϫ g for 5 min at 4°C. The pellet was washed with ice-cold HBSS with 10 mM glucose and resuspended with 200 l of HClO 4 (4%) for 30 min, and 1.5 M KOH was added to reach neutral pH. Samples were centrifuged at 15,000 ϫ g for 30 min at 4°C, and the supernatant was frozen at Ϫ20°C. Accumulation of cAMP was measured with Cyclic AMP ( 3 H) Assay System (GE Healthcare) as described by the manufacturer.
Dynamic mass redistribution assays. Dynamic mass redistribution (DMR) was determined using an EnSpire Multimode Plate Reader (PerkinElmer Life and Analytical Sciences). Refractive waveguide grating optical biosensors, integrated in 384-well microplates, allow extremely sensitive measurements of changes in local optical density in a detecting zone up to 150 nm above the surface of the sensor. Cellular mass movements induced during receptor activation were detected by illuminating the underside of the biosensor with polychromatic light and measured as changes in wavelength of the reflected monochromatic light that is a sensitive function of the index of refraction. The magnitude of this wavelength shift (in picometers) is directly proportional to the amount of DMR. Briefly, 24 h before the assay, cells were seeded at a density of 5000 cells per well in 384-well sensor microplates with 30 l of growth medium and cultured for 24 h (37°C, 5% CO 2 ) to obtain 70 -80% confluent monolayers. Cells were washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15) and incubated 2 h in 40 l/well assay buffer with 0.1% DMSO at 24°C, the sensor plate was scanned, and a baseline optical signature was recorded before incubating the indicated antagonists for 30 min and adding 10 l of agonist dissolved in assay buffer containing 0.1% DMSO. DMR responses were monitored for at least 8000 s. Kinetic results were analyzed using EnSpire Workstation Software version 4.10 (EnSpire Software), and curves were normalized with respect to the baseline.
In vivo VTA dendritic dopamine release. Male Sprague Dawley rats (3 months old; Charles River Laboratories) were used. Animals were housed two per cage and kept on a 12 h dark/light cycle with food and water available ad libitum. Experiments were performed during the light cycle. All animals used in the study were maintained in accordance with the guidelines of National Institutes of Health animal care, and the animal research conducted to perform this study was reviewed and approved by the National Institute on Drug Abuse Intramural Research Program Animal Care and Use Committee (Protocol 12-BNRB-73). Rats were deeply anesthetized with 3 ml/kg Equithesin [4.44 g of chloral hydrate, 0.972 g of Na pentobarbital, 2.124 g of MgSO 4 , 44.4 ml of propylene glycol, 12 ml of ethanol, and distilled H 2 O up to 100 ml of final solution (National Institute on Drug Abuse Pharmacy)] and implanted unilaterally in the VTA (coordinates in mm from bregma with a 10°angle in the coronal plane: anterior, 5.6; lateral, 2.4; vertical, 9) with a specially designed microdialysis probe that allows the direct infusion of large peptides within the sampling area. After surgery, rats were allowed to recover in hemispherical CMA-120 cages (CMA Microdialysis) equipped with two-channel overhead fluid swivels (Instech) connected to a sample collector (CMA 470; CMA). Twenty-four hours after implanting the probe, in the middle of the light period of the light/dark cycle, experiments were performed on freely moving rats in the same hemispherical home cages in which they recovered overnight from surgery. An ACSF (in mM: 144 NaCl, 4.8 KCl, 1.7 CaCl 2 , and 1.2 MgCl 2 ) was pumped through the probe at a constant rate of 1 l/min. After a washout period of 90 min, dialysate samples were collected at 20 min intervals. For peptide infusion, orexins and CRF were dissolved in ACSF to a final concentration of 10 M, whereas HIV TAT-fused peptides were dissolved in 0.1% DMSO in ACSF to a final concentration of 30 M (TM1 and TM5) or 60 M (TM7). All peptides were injected with a 1 l syringe (Hamilton) driven by an infusion pump and coupled with silica tubing (73 m inner diameter; Polymicro) to the microdialysis probe infusion port (dead volume, 40 nl), which was primed with ACSF and plugged during implantation. All peptides were delivered at a rate of 16.6 nl/min. The OX 1 R antagonist SB334667 was dissolved in sterile saline and administered intraperitoneally (10 mg/kg) 40 min before peptide infusion. The CRF 1 R antagonist NBI27914 was dissolved in 5% DMSO in water and administered intraperitoneally (10 mg/kg) 40 min before peptide infusion. The 1 R agonist PRE-084 was dissolved in ACSF at a concentration of 100 M and was perfused through the microdialysis probe (reverse dialysis). Cocaine HCl was administered intraperitoneally 24 h before the start of the microdialysis experiment at a dose of 15 mg/kg. At the end of the experiment, rats were given an overdose of Equithesin, the brains were extracted and fixed in formaldehyde, and probe placement was verified using cresyl violet staining. Dopamine content was measured by HPLC coupled with a coulometric detector (5200a Coulochem III; ESA).
Statistics. Sample sizes were between 5 and 10, which our previous published work indicated are sufficient to perform appropriate statistical analysis. Parametric statistics (unpaired t test and one-way or repeatedmeasures ANOVA) were used, because the different groups analyzed showed normality and homogeneity of variance. GraphPad Prism software version 5 was used for the statistical analysis.
Results
Expression and functional characterization of heteromers between OX 1 R and CRF 1 R in transfected cells BRET and PLA experiments were performed in HEK-293T cells transfected with OX 1 R-RLuc and CRF 1 R-YFP (Figs. 1 A, B) .
These fusion proteins properly trafficked to the cell membrane, as shown by confocal microscopy (Fig. 1C) , and were functional, as shown by comparing their ability to increase ERK1/2 phosphorylation with that of native receptors (Fig. 1D) . BRET saturation curves were obtained in cells expressing OX 1 R-RLuc and increasing amounts of CRF 1 R-YFP (Fig. 1A) , with BRET max of 186 Ϯ 6 mBU and BRET 50 of 54 Ϯ 7, indicating that these receptors can indeed form heteromers. As a negative control, a low and linear BRET was detected in cells expressing CRF 1 R-RLuc and increasing amounts of GHS 1a R fused to YFP (Fig. 1A) . Accordingly, receptor heteromers were also visualized as red spots by using PLA in cells expressing OX 1 R-RLuc and CRF 1 R-YFP but not in cells expressing CRF 1 R-RLuc and GHSR 1a -YFP (Fig. 1B) .
CRF or the OX 1 R agonist orexin-A induced ERK1/2 phosphorylation in cells coexpressing CRF 1 R and OX 1 R (Fig. 2A) . Orexin-A-induced signaling was inhibited by the OX 1 R antago- 3 g; B) or OX 1 R-RLuc cDNA (0.4 g; B) or both (A, C) pretreated (10 min) with vehicle, the OX 1 R antagonist SB334667 (SB; 1 M), or the CRF 1 R antagonist NBI27914 (NBI; 1 M), followed by treatment with medium, CRF (100 nM), orexin-A (50 nM), or both for 7 min (A, B) or for 2.5, 5, 7.5, 19, and 15 min (C). Values are means Ϯ SEMs of five to six experiments per group and are expressed as percentage of basal levels (100%; dotted line). D, Akt phosphorylation was determined in cells transfected with CRF 1 R-YFP cDNA (0.3 g) and OX 1 R-RLuc cDNA (0.4 g), pretreated (10 min) with vehicle, the OX 1 R antagonist SB334667 (SB; 1 M), or the CRF 1 R antagonist NBI27914 (NBI; 1 M), followed by treatment (7 min) with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means Ϯ SEMs of six to eight experiments per treatment and are expressed as percentage of basal levels (100%; dotted line). E, F, ␤-Arrestin 2 recruitment measured by BRET in cells transfected with CRF 1 R-YFP cDNA (0.3 g; E, white bars) or OX 1 R-YFP cDNA (0.4 g; E, black bars), or both (F ) and ␤-arrestin 2-RLuc cDNA (0.5 g). Cells were pretreated (10 min) with vehicle, SB334667 (SB; 1 M), or NBI27914 (NBI; 1 M), followed by treatment (7 min) with CRF (100 nM), orexin-A (50 nM), or both. Values are means Ϯ SEMs of five to six experiments per treatment. G, H, cAMP accumulation was determined in cells transfected with CRF 1 R-YFP cDNA (0.3 g; G, white bar) or OX 1 R-RLuc cDNA (0.4 g; G, black bar), or both (H ). Cells were pretreated (10 min) with vehicle, the OX 1 R antagonist SB334667 (SB; 1 M), or the CRF 1 R antagonist NBI27914 (NBI; 1 M), followed by treatment (7 min) with medium, CRF (100 nM), orexin-A (50 nM), or both. Values are means Ϯ SEMs of six to eight experiments per treatment and expressed as increases of basal levels or as decreases of forskolin-induced cAMP accumulation (for orexin-A; 100%; dotted line). In A, B, D-F, and H, One-way ANOVA followed by nist SB334867 and the CRF 1 R antagonist NBI27914, that did not modify basal levels by themselves, and vice versa, CRFinduced ERK1/2 phosphorylation was antagonized by both NBI27914 and SB334667. Thus, CRF 1 R-OX 1 R heteromers display cross-antagonism, a property seen in previous receptor heteromers (Guitart et al., 2014; . A negative crosstalk was also observed because ERK1/2 phosphorylation during coactivation of both receptors was significantly lower compared with that induced by single activation of either CRF 1 R or OX 1 R (Fig. 2A) . Cross-antagonism and negative crosstalk were not attributable to either the lack of ligand specificity, because they were not observed in cells expressing single receptors (Fig. 2B) , or a change in the shape of the time-response curve of ERK1/2 phosphorylation (Fig. 2C) . Negative crosstalk and cross-antagonism were also observed at the level of Akt phosphorylation (Fig. 2D) . ␤-Arrestin recruitment was also analyzed, because it has been shown to mediate ERK1/2 and Akt phosphorylation for several GPCRs (Fig. 2E) , indicating both the specificity of the ligands and the ability of these receptors to recruit ␤-arrestin 2 when activated. Significantly, not only CRF but also orexin-A significantly increased BRET values in cells expressing ␤-arrestin 2-RLuc, CRF 1 R-YFP, and OX 1 R (Fig. 2F ). During coactivation with both agonists CRF and orexin-A, a negative crosstalk was observed at the level of ␤-arrestin 2 recruitment. Furthermore, cross-antagonism could also be demonstrated, and CRF-promoted and orexin-Apromoted ␤-arrestin 2 recruitment were counteracted by SB334867 and NBI27914, respectively (Fig. 2F) .
Orexin-A decreased forskolin-stimulated cAMP in cells expressing OX 1 R, indicating receptor coupling to a G i -protein, and CRF promoted an increase in cAMP production in cells expressing CRF 1 R, indicating receptor coupling to a G s -protein (Fig. 2G) . The same findings were observed in cells coexpressing OX 1 R and CRF 1 R, suggesting that the receptors can signal independently through their preferred G-proteins in the CRF 1 R-OX 1 R heteromer (Fig. 2H ) . Crossantagonism could also be observed at the adenylyl-cyclase level in cells coexpressing OX 1 R and CRF 1 R. Thus, orexin-A-induced inhibition of forskolin-stimulated cAMP accumulation was counteracted not only by the OX 1 R antagonist SB334867 but also by the CRF 1 R antagonist NBI27914. Equally, CRF-induced cAMP accumulation was counteracted by both NBI27914 and SB334867 (Fig. 2H ) . A canonical G s -G i interaction at the adenylyl-cyclase level could not be observed during coactivation of both receptors with CRF and orexin-A, showing cAMP accumulation similar to that obtained with CRF alone (Fig. 2H ) . This would indicate a negative crosstalk by which CRF 1 R activation counteracts OX 1 R signaling through G i in the CRF 1 R-OX 1 R heteromer. These findings were supported with experiments using label-free DMR technology, which allows measuring G-proteinmediated signaling in living cells. Agonist-induced timeresponse curves in the absence or presence of pertussis toxin (PTX) or cholera toxin (CTX) were obtained in cells expressing both OX 1 R and CRF 1 R (Fig. 3A) . The maximum response in- 3 g; B) . Cells were pretreated (overnight) with (A-D) vehicle, PTX (10 ng/ml), or CTX (100 ng/ml) or vehicle, the OX 1 R antagonist SB334667 (SB; 1 M) or the CRF 1 R antagonist NB127914 (NBI; 1 M), followed by treatment (7 min) with CRF (100 nM), orexin-A (50 nM), or both (E). A-C, Representative picometer shifts of reflected light wavelength (picometers) versus time; each curve shows the mean of a representative optical trace experiment performed in triplicate. D, E, Maximum responses are derived from the resulting picometer shifts of reflected light wavelength (picometers) versus time curves. Values are means Ϯ SEMs of four to five experiments per group. One-way ANOVA followed by Bonferroni's multiple comparison post hoc tests show significant agonist effect versus basal values (***p Ͻ 0.001), no significant effect of CRF plus orexin-A treatment versus CRF or orexin-A treatment, and significant effect of agonist plus antagonist or toxin treatment versus agonist alone ( &&& p Ͻ 0.001).
duced by orexin-A or CRF (derived from time-response curves) was significantly inhibited with pretreatment with either PTX or CTX (Fig. 3D) . Conversely, in cells only expressing CRF 1 R, the effect of CRF was inhibited by CTX but not with PTX ( Fig. 3B) , whereas in cells only expressing OX 1 R, the effect of orexin-A was only inhibited by PTX (Fig. 3C ). These results demonstrate that the heteromer can interact simultaneously with both G i -and G s -proteins. Negative crosstalk and cross-antagonism were also observed by DMR. The effect (maximum response) of CRF or orexin-A was inhibited by both NBI27914 and SB334867, and the coactivation with CRF and orexin-A produced a lower response than the one obtained by single activation (Fig. 3E) . These results suggest strongly that negative crosstalk and cross-antagonism observed for G-protein-dependent and ␤-arrestin-dependent signaling pathways constitute biochemical characteristics of CRF 1 R-OX 1 R heteromers. BiFC experiments (Fig. 4A) were performed to check the ability of peptides with the amino acid sequence of OX 1 R TM domains to destabilize CRF 1 R-OX 1 R heteromer, as described recently for the dopamine D 1 -D 3 receptor heteromer (Guitart et al., 2014) . HIV TAT peptides fused to OX 1 R TM1, TM5, and TM7 peptides were used. Significant fluorescence could be detected in HEK-293T cells transfected with CRF 1 R fused to the N-terminal fragment of YFP Venus (nVenus) and OX 1 R fused to the C-terminal fragment YFP Venus (cVenus) as a result of YFP Venus reconstitution by CRF 1 R-OX 1 R heteromerization. Treatment with OX 1 R TM1 and TM5 peptides alone or in combination, but not TM7, inhibited YFP Venus reconstitution, and the effect of TM1 plus TM5 was more pronounced than the effect obtained by either peptide alone (Fig.  4B ). ERK1/2 phosphorylation crosstalk and cross-antagonism experiments were then performed in cells pretreated with OX 1 R TM1 (Fig. 4C) or TM5 (Fig. 4D) peptides. Both peptides counteracted the negative crosstalk and cross-antagonism (Fig. 4C,D) . Importantly, TM7 peptide, which was not able to alter the structure of CRF 1 R-OX 1 R in BiFC experiments, was also ineffective at counteracting the negative crosstalk and cross-antagonism (Fig. 4E) . None of the peptides themselves significantly changed signaling from each of the receptors when activated alone with their respective agonists ( Fig. 4C-E ). These results demonstrate that the negative crosstalk and cross-antagonism depend on the integrity of the quaternary structure of the CRF 1 R-OX 1 R heteromer and, therefore, that constitute biochemical characteristics of the heteromer. Two CRF 1 R functional mutants were used to provide some insight about the conformational changes involved in the negative crosstalk between ligands binding to the CRF 1 R-OX 1 R heteromer: (1) a truncated mutant (CRF 1 R433) that lacks a large part of the N-terminal domain and is not able to bind CRF but can still be activated by a small peptide that corresponds to the N-terminal part of CRF (peptide 14b, which binds to the juxtamembrane activating domain of CRF 1 R; Devigny et al., 2011); and (2) a receptor that contains a mutation in the third intracellular loop and has enhanced constitutive activity (CRF 1 R432). Both mutants were able to form heteromers with OX 1 R as detected by BRET experiments without significant differences in BRET max and BRET 50 with respect to the CRF 1 R (Fig. 5 A, B) . As expected, CRF or orexin-A did not induce ERK1/2 phosphorylation in HEK-293T cells expressing CRF 1 R433 alone (Fig.  5C ). Orexin-A, but not CRF, was able to signal in cells expressing CRF 1 R433-OX 1 R heteromers, but orexin-A-induced signaling was not modified by CRF or the CRF 1 R antagonist NBI27914 (Fig. 5 D, E) . Nevertheless, in these cells, peptide 14b promoted ERK1/2 phosphorylation, and a negative crosstalk was observed between orexin-A and peptide 14b (Fig. 5F ). These results indicate that an active conformation of the CRF 1 R is involved with the negative crosstalk of receptor agonists in the CRF 1 R-OX 1 R heteromer. This was further corroborated using the CRF 1 R432 mutant, which displays high constitutive activity. Single expression of CRF 1 R432 showed increased basal ERK1/2 phosphorylation (compared with nontransfected cells), which could not be increased further by CRF (Fig. 5G) . The same findings were also obtained in cells expressing CRF 1 R432 and OX 1 R (Fig. 5H ) . In addition, orexin-A did not increase MAPK signaling, in agreement with the active conformation of CRF 1 R facilitating an allosteric inhibition of the orexin-A signaling (Fig. 5H ) .
CRF 1 R-OX 1 R heteromers in the VTA control dendritic dopamine release In rat VTA slices, orexin-A and CRF promoted ERK1/2 phosphorylation (Fig.  6A) , coactivation with orexin-A and CRF showed negative crosstalk, and both the CRF 1 R antagonist NBI27914 and the OX 1 R antagonist SB334867, which do not modify basal levels by themselves, antagonized the effect of orexin-A and CRF, thus showing cross-antagonism (Fig. 6A ). Crosstalk and cross-antagonism disap- peared when VTA slices were treated with the CRF 1 R-OX 1 R destabilizing peptides OX 1 R TM1 plus TM5 (10 M; Fig. 6B ), whereas the negative control TM7 peptide (at the same total peptide concentration, 20 M) was ineffective (Fig. 6B) , which demonstrates the presence of CRF 1 R-OX 1 R heteromers in the VTA.
To investigate the functional role of CRF 1 R-OX 1 R heteromers in the VTA, we analyzed dopamine release in the VTA using in vivo microdialysis experiments (Fig. 6C-F ) . Dendritic dopamine release by mesencephalic dopaminergic cells resembles that of the terminal regions, possessing a similar uptake mechanism and a finite releasable storage pool (Kita et al., 2009 ). Furthermore, local dopamine release in the VTA is a correlate of dopaminergic cell firing (Legault and Wise, 1999) . Initial attempts to perfuse orexin-A through the dialysis probe (reverse dialysis) were unsuccessful, which included testing of different compositions of ACSF and different dialysis membranes of different materials and different cutoff, as analyzed with mass-spectrometry analysis of in vitro-recovered dialysates (data not shown). A specialized probe with an embedded silica infusion port was designed ( Fig. 7) that allowed simultaneous constant slow delivery (1 l/h) of large peptides (ligands and OX 1 R TM peptides) in the same brain region where the microdialysis probe is sampling the extracellular concentration of dopamine. VTA infusion of orexin-A (10 M) for 60 min produced dopamine release, which remained elevated Ͼ1 h after withdrawal (Fig. 6D) . The average basal dialysate concentration of dopamine of a total of 121 animals was 2.37 Ϯ 0.15 nM (mean Ϯ SEM). This effect was attributable to selective activation of OX 1 R, because it was not reproduced by a 10 M infusion of the selective OX 2 R agonist orexin-B (Sakurai et al., 1998; de Lecea et al., 1998) and was counteracted by the previous systemic administration of an effective dose (10 mg/kg, i.p.) of the selective OX 1 R receptor antagonist SB334867 (Richards et al., 2008;  Fig. 6D ). The infusion of CRF (10 M) or the systemic administration of an effective dose (10 mg/kg, i.p.) of the CRF 1 R antagonist NBI27914 did not produce any significant change in the extracellular concentration of dopamine, but both counteracted the effect of orexin-A (Fig. 6E) , demonstrating the negative crosstalk and cross-antagonism. These results strongly suggest that dendritic VTA dopamine release is under the control of CRF 1 R-OX 1 R heteromers. This was further demonstrated using CRF 1 R-OX 1 R destabilizing peptides. Infusion of OX 1 R TM1 (30 M) plus TM5 (30 M) peptides but not the control TM7 peptide (at the same total peptide concentration, 60 M) counteracted the orexin-A-CRF negative crosstalk (Fig. 6F ) . The effect of the TM peptides was not long lasting, probably because of a faster clearance compared with that of the larger and more hydrophilic orexin-A and CRF molecules. These results demonstrate that CRF 1 R-OX 1 R heteromers modulate VTA dopamine release. cross-antagonism between CRF 1 R and OX 1 R ligands on MAPK signaling (Fig. 8A, black, bars) and ␤-arrestin 2 recruitment (Fig.  8B , black bars) that was seen in the absence of cocaine (Fig. 8 A, B , white bars). Thus, cocaine blocks the allosteric intermolecular interactions in the CRF 1 R-OX 1 R heteromers that conduce the crosstalk and cross-antagonism between CRF 1 R and OX 1 R ligands.
We next explored the effect of cocaine in the rat VTA. The extracellular level of cocaine in the rat brain reached after pharmacologically significant doses is estimated to be 15 M (Pettit et al., 1990) . A higher cocaine concentration (100 M) was then used to allow diffusion into the VTA slices. Cocaine pretreatment for 4 h counteracted the negative crosstalk of orexin-A and CRF on ERK1/2 phosphorylation. Furthermore, crossantagonism of SB334867 or NBI27914 on ERK1/2 phosphorylation induced by CRF or orexin-A was not observed (Fig.  8C) . Therefore, cocaine also disrupts the allosteric interactions within the CRF 1 R-OX 1 R heteromer in the VTA.
1 Rs mediate the disruptive effects of cocaine on CRF 1 R-ORX 1 R heteromer function It has been found recently that cocaine can disrupt allosteric interactions between ligands in dopamine D 1 -histamine H 3 receptor (H 3 R) heteromers by acting on 1 Rs that oligomerize with the heteromer . We explored whether this mechanism could be involved in the disruptive effects of cocaine on CRF 1 R-ORX 1 R heteromer function. A saturable BRET curve was obtained in HEK-293T cells expressing CRF 1 R-RLuc and increasing concentrations of 1 R-YFP (Fig. 9A) , indicating a direct interaction between 1 R and CRF 1 R. Cocaine produced a significant change in BRET max and BRET 50 BRET values (Fig.  9A) , indicating a cocaine-induced change in the quaternary structure of the 1 R-CRF 1 R oligomers. Conversely, no significant BRET was detected in cells expressing OX 1 R-RLuc and 1 R-YFP in the absence or presence of cocaine (Fig. 9B) . These results suggest that 1 R can interact with CRF 1 R-OX 1 R heteromers by binding to CRF 1 R in the heteromer. The heterotrimeric complex expression was demonstrated with SRET ( Fig. 10A ; Carriba et al., 2008) . In HEK-293T cells expressing a constant amount of OX 1 R-RLuc and 1 R-YFP and increasing amounts of CRF 1 RCherry, a net SRET saturation curve was obtained (Fig. 10B) with an SRET max of 0.31 Ϯ 0.01 mSU and a SRET 50 of 0.08 Ϯ 0.01. These results provide evidence for the existence of 1 R-CRF 1 R-OX 1 R oligomers. Cocaine produced a significant change in SRET max and SRET 50 values (SRET max of 0.19 Ϯ 0.03 mSU and a SRET 50 of 0.056 Ϯ 0.002), indicating a cocaine-induced change in the quaternary structure of the 1 R-CRF 1 R-OX 1 R oligomers. The involvement of 1 R in the effects of cocaine on CRF 1 R-OX 1 R heteromers function in the VTA was demonstrated by using selective 1 R ligands. In VTA slices, pretreatment for 4 h with the 1 R agonist PRE-084 (Garcés-Ramírez et al., 2011) counteracted the negative crosstalk on ERK1/2 phosphorylation detected during CRF and orexin-A coadministration (Fig. 10C) . Moreover, pretreatment with the 1 R antagonist PD144418 (Akunne et al., 1997) blocked the effect of cocaine, and the negative cross- talk between CRF and orexin-A was still present with preincubation of cocaine and PD144418 (Fig. 10D) .
Cocaine exerts its stimulant effects predominantly by its ability to block the dopamine transporter (DAT; Kita et al., 2009 ). To dissect the 1 R effects in microdialysis experiments, we used the selective 1 R agonist PRE-084, which reproduced the effects of cocaine in the in vitro experiments and has very low affinity for DAT (Garcés-Ramírez et al., 2011) . Direct perfusion of the 1 R agonist PRE-084 (100 M) through the microdialysis probe did not modify the extracellular concentration of dopamine (Fig.  10F ) but counteracted the negative crosstalk between orexin-A and CRF. Thus, in the presence of PRE-084, orexin-A plus CRF produced an increase in extracellular dopamine that was larger than the one induced by orexin-A alone (Fig. 10E) . In fact, in the presence of PRE-084, orexin-A was more effective, particularly during the first two samples (40 min) after its infusion. Interestingly, CRF, which was ineffective by itself, also produced a prolonged significant elevation of extracellular dopamine during perfusion with the 1 R agonist (Fig. 10F ) . These results match with the in vitro experiments and indicate the existence of a negative crosstalk between orexin-A and CRF, which is counteracted by 1 R activation. These striking results are in total agreement with 1 R-CRF 1 R-OX 1 R oligomers modulating VTA dopamine release.
We then studied whether one single administration of cocaine (15 mg/kg) could also reproduce the effects of the acute perfusion of the 1 R agonist PRE-084 attributable to a long-term disruption of the allosteric interactions in the CRF 1 R-OX 1 R heteromer, as demonstrated recently for 1 R-D 1 R-H 3 R oligomers . In fact, a significant elevation in the extracellular concentration of VTA dopamine was observed after infusion of CRF or coinfusion of orexin-A and CRF (Fig. 10G ).
Discussion
Class B GPCR CRF 1 R has been shown previously to homomerize (Milan-Lobo et al., 2009 ) and also heteromerize with the class A GPCRs for vasopressin and its non-mammalian vertebrate homolog vasotocin in transfected cells (Mikhailova et al., 2007; Murat et al., 2012) . Similarly, evidence has been reported for OX 1 R homomerization and heteromerization in artificial cell systems (Ellis et al., 2006; Jäntti et al., 2014) . However, although colocalized in the VTA, CRF 1 R-OX 1 R heteromerization has not been described, and, in fact, it has been argued that independent actions of CRF and orexin-A in the VTA are involved in reinstatement of cocaine seeking . In the present study, we demonstrate the existence of functional CRF 1 R-OX 1 R heteromers in transfected cells and the VTA, in which they exert a significant functional control of dopaminergic cells. By means of allosteric interactions within the CRF 1 R-OX 1 R heteromer, CRF and orexin-A antagonize each other's ability to signal and promote VTA dendritic dopamine release, indicating that this heteromer should play a significant role under stress conditions, during concomitant CRF and orexin-A VTA release. Additional important findings were the evidence for oligomerization of 1 R with the CRF 1 R-OX 1 R heteromer and the ability of 1 R agonists, including cocaine, to modify the quaternary structure of the heteromer to block the functional allosteric interactions between orexin-A and CRF within the heteromer.
Molecular interactions between CRF 1 R and OX 1 R were demonstrated in HEK-293T cells by using different approaches, and ␤-arrestin 2-RLuc cDNA (0.5 g). Cells were pretreated (2 h) with cocaine (30 M, black bars) or with medium (white bars) and (10 min) with vehicle, SB334667 (SB; 1 M), or NBI27914 (NBI; 1 M), followed by treatment (7 min) with CRF (100 nM), orexin-A (50 nM), or both. Values are means Ϯ SEMs of five to six experiments per group. One-way ANOVA followed by Bonferroni's multiple comparison post hoc test shows significant differences of agonist treatment versus basal (**p Ͻ 0.01 and ***p Ͻ 0.001) or agonist plus antagonist treatment versus agonist alone ( &&& p Ͻ 0.001). C, ERK1/2 phosphorylation in rat VTA slices preincubated (4 h) with cocaine (100 M, black bars) or with vehicle (white bars) and (30 min) with vehicle, SB334667 (SB; 10 M), or NBI27914 (NBI; 10 M), followed by treatment (10 min which included BRET, fluorescence complementation, and PLA, but also additional demonstration came from results of signaling experiments indicating the expression of CRF 1 R-OX 1 R heteromers at the membrane level. To our knowledge, the ability of an antagonist of one receptor to block the agonist-mediated signaling of another receptor has only been reported in the frame of receptor heteromerization . Also, the ability of orexin-A to induce an interaction between ␤-arrestin 2-RLuc and CRF 1 R-YFP indicates recruitment of ␤-arrestin 2 to the CRF 1 R-OX 1 R heteromer. Moreover, the surprising ability of PTX to counteract G s -mediated CRF 1 R signaling and that of CTX to block G i -mediated OX 1 R signaling indicate that the CRF 1 R-OX 1 R heteromer can interact simultaneously with both G i and G s proteins showing an interdependence of G i and G s protein function in the heteromer. Demonstration of unique biochemical properties of a receptor heteromer requires their dependence on the structural integrity of the heteromer , which can be destabilized, for instance, by interfering synthetic peptides with the amino acid sequence corresponding to some TM or intracellular domains of one of the protomers (Azdad et al., 2009; He et al., 2011; Guitart et al., 2014) . BRET and complementation experiments in transfected cells demonstrated that specific OX 1 R TM peptides and 1 R agonists significantly modify the quaternary structure of the CRF 1 R-OX 1 R heteromer. Therefore, both were used as tools to interrogate the CRF 1 R-OX 1 R heteromer function. In fact, both OX 1 R TM peptides and 1 R agonists significantly counteracted negative crosstalk and cross-antagonism of CRF 1 R and OX 1 R ligands, demonstrating that they constitute biochemical properties of the CRF 1 R-OX 1 R heteromer. The application of the same tools in situ and in vivo, in VTA slices and in microdialysis experiments, further demonstrated the presence of CRF 1 R-OX 1 R heteromers in the VTA. The very different quantitative effect of OX 1 R TM peptides versus 1 R agonists observed in vivo, with a respective transient versus long-lasting (apparently irreversible) destabilization of CRF 1 R-OX 1 R-heteromer function, should be related to the different molecular mechanisms and different modifications of the quaternary structure of the heteromer involved. Particularly significant will be the elucidation of the apparently irreversible effect of 1 R agonists, such as cocaine.
An important amount of experimental data demonstrates the involvement of 1 R in many pharmacologic, including rewarding, effects of cocaine (Maurice and Su, 2009; Robson et al., 2012) . Recent studies describe a role of oligomerization of 1 R with D 1 R or D 2 R in the acute psychostimulants effects of cocaine and with voltage-gated Kv1.2 potassium channels in long-lasting behavioral responses (Kourrich et al., 2013) . Also, oligomerization of 1 R, D 1 R, and H 3 Rs ( 1 R-D 1 R-H 3 R heteromers) has been involved in the neurotoxic effects of cocaine . Interestingly, when comparing the effects of cocaine binding with either 1 R-D 1 R-H 3 R or 1 R-CRF 1 R-OX 1 R oligomers, a common mechanism emerges, the loss of the allosteric interactions between ligands in the heteromer.
The present results strongly suggest that CRF 1 R-OX 1 R heteromers localized in the VTA convey the previously established significant control of dopaminergic cell function by CRF and orexin-A in cocaine-treated animals. The counteraction of the negative crosstalk between orexin-A and CRF in the VTA by the simultaneous application of the 1 R agonist PRE-084 or by the previous administration of cocaine provides a mechanism by which CRF can only induce VTA dendritic dopamine release in animals exposed previously to cocaine . Under these conditions, CRF 1 R-mediated signaling is not inhibited by a tonic activation of OX 1 R by endogenous orexin-A. Counteraction of the allosteric interactions between agonists in the CRF 1 R-OX 1 R heteromer can also explain the apparent CRF-independent ability of orexin-A to release dopamine in the VTA and to induce cocaine seeking . Remarkably, in the present study, cocaine produced a modification of CRF 1 R-OX 1 R heteromer function that was observed 24 h after one single systemic administration. Very similar findings were reported recently for 1 R-D 1 R-H 3 R oligomers, in which the ability of H 3 R ligands to modulate D 1 R-mediated signaling was also disrupted 24 h after one single systemic administration of cocaine . Therefore, one single administration could explain some effects of cocaine attributed previously to its repeated administration.
Of the many new questions this study raises is the identification of the precise localization of CRF 1 R-OX 1 R heteromers in the VTA. Both receptors are potentially colocalized in dopaminergic cells and their glutamatergic afferents Borgland et al., 2010) , in which CRF 1 R-OX 1 R heteromers could directly or indirectly control the extracellular levels of dopamine in the VTA. Second, our data indicate that, under basal conditions, the effects of CRF and orexin-A in the VTA are interdependent and mediated by CRF 1 R-OX 1 R heteromers, but they also suggest that endogenous 1 R ligands should be able to act as cocaine and therefore promote independent effects of CRF and orexin-A. Those ligands and the conditions under which they are produced in the VTA still need to be determined. Third is to understand the potential changes in 1 R-CRF 1 R-OX 1 R oligomers in acute versus longterm exposure to cocaine. It has been shown that repeated cocaine exposure increases the levels of 1 R in the brain (Robson et al., 2012) , and cocaine-mediated upregulation of striatal 1 R has been reported to increase the presence of 1 -Kv1.2 oligomers at the plasma membrane, which has been suggested to be involved in sensitization to its psychostimulants effects (Kourrich et al., 2013) . Therefore, upregulation of 1 R in the VTA could increase the proportion of 1 R-CRF 1 R-OX 1 R oligomers, leading to more profound cocaine-induced changes in the control of VTA dendritic dopamine release by CRF and orexin-A. Those changes could explain the CRF 1 R-dependent augmented cocaine seeking in response to stress or CRF delivered into the VTA after longaccess self-administration (Blacktop et al., 2011) . Altogether, the present study demonstrates a significant functional and pharmacological role of 1 R in the modulation of CRF 1 R-OX 1 R heteromers during physiological conditions and under conditions of acute cocaine administration and withdrawal. Addressing the study of 1 R-CRF 1 R-OX 1 R oligomers in animal models of psychostimulant abuse should provide significant additional information that would support their role as new therapeutic targets. ) and increasing amounts of CRF 1 R-Cherry cDNA (0.05-0.6 g) in controls (black curve) or cocaine-treated (30 min, 30 M; red curve) cells. SRET, expressed as mSU, is given as a function of the ratio between the fluorescence of the acceptor (Cherry) and the Luciferase activity of the donor (RLuc). Values are means Ϯ SEMs of seven to eight replications of one independent experiment per point. C, ERK1/2 phosphorylation in rat VTA slices preincubated (4 h) with the 1 R agonist PRE-084 (1 M), followed by treatment (10 min) with CRF (1 M), orexin-A (1 M), or both. D, ERK1/2 phosphorylation in rat VTA slices preincubated (4 h) with the 1 R antagonist PD144418 (1 M), with or without cocaine (100 M), followed by treatment (10 min) with CRF (1 M), orexin-A (1 M), or both. In C and D, values are means Ϯ SEMs of five to six experiments per group expressed as percentage of basal values (100%). One-way ANOVA followed by Bonferroni's multiple comparison post hoc test showed significant differences versus basal (*p Ͻ 0.05) and CRF plus orexin-A treatment versus CRF or orexin-A treatment ( # p Ͻ 0.05). E-G, Dopamine (DA) levels in dialysates sampled from the VTA after slow infusion (1 l/h) of orexin-A (1 l, 10 M) and/or CRF (1 l, 10 M) with preinfusion and coinfusion of the 1 R agonist PRE-084 (PRE; 100 M) or previous systemic (intraperitoneal) administration of cocaine (COC; 15 mg/kg; 24 h before the microdialysis experiment). Values are means Ϯ SEMs of 7-10 experiments per group and are expressed as percentage of basal values (average of first 3 values before orexin-A or CRF infusion). A repeated-measures ANOVA (including only the basal value before orexin-A or CRF infusion) followed by Bonferroni's multiple comparison post hoc test showed significant differences (filled symbols, p Ͻ 0.05) versus the last basal values before orexin-A or CRF infusion. Data on the effect of infusion of orexin-A alone in E are the same shown in Figure 6D -F.
